Northern Trust Corp Has $11.67 Million Stock Holdings in Novavax, Inc. (NASDAQ:NVAX)

Northern Trust Corp boosted its position in shares of Novavax, Inc. (NASDAQ:NVAX) by 6.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,451,715 shares of the biopharmaceutical company’s stock after buying an additional 83,503 shares during the quarter. Northern Trust Corp owned approximately 0.91% of Novavax worth $11,672,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Franklin Resources Inc. lifted its holdings in Novavax by 300.4% during the 3rd quarter. Franklin Resources Inc. now owns 97,162 shares of the biopharmaceutical company’s stock worth $1,226,000 after buying an additional 72,894 shares in the last quarter. Shah Capital Management lifted its holdings in Novavax by 13.6% during the 4th quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock worth $89,637,000 after buying an additional 1,333,305 shares in the last quarter. Arizona State Retirement System lifted its holdings in Novavax by 14.9% during the 4th quarter. Arizona State Retirement System now owns 41,793 shares of the biopharmaceutical company’s stock worth $336,000 after buying an additional 5,407 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Novavax by 0.4% during the 4th quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company’s stock worth $3,509,000 after buying an additional 1,664 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Novavax by 28.8% during the 4th quarter. JPMorgan Chase & Co. now owns 76,576 shares of the biopharmaceutical company’s stock worth $616,000 after buying an additional 17,101 shares in the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Stock Performance

Shares of Novavax stock opened at $6.73 on Friday. The firm has a fifty day moving average of $6.69 and a two-hundred day moving average of $7.91. The stock has a market capitalization of $1.09 billion, a price-to-earnings ratio of -2.98, a PEG ratio of 2.85 and a beta of 3.21. Novavax, Inc. has a 52 week low of $5.01 and a 52 week high of $23.86.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $2.93 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $2.22. The firm had revenue of $666.66 million during the quarter, compared to the consensus estimate of $204.08 million. During the same quarter in the prior year, the company earned ($1.05) EPS. Novavax’s quarterly revenue was up 610.3% on a year-over-year basis. As a group, research analysts forecast that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on NVAX shares. BTIG Research started coverage on Novavax in a report on Friday, February 28th. They set a “buy” rating and a $19.00 price objective on the stock. TD Cowen upgraded shares of Novavax to a “hold” rating in a research report on Thursday, February 27th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Novavax from $9.00 to $7.00 and set an “underweight” rating for the company in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $19.00.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.